1 The Rise of Hybrid Trials The Rise of Hybrid Trials Authored by: Melissa Newara, eSource Subject Matter Expert1 The Rise of Hybrid Trials Prior to 2020, the answer was likely not very much. Although decentralized trials (DCT) existed prior to the pandemic, COVID-19 undoubtedly had a large impact on the rapid adoption of DCT technologies. As many as 76% of clinical trials had to shift some or all of their trial operations to decentralized solutions. 1 As global regulators became more accepting of these novel technologies and patients became accustomed to using them, it begged the question: is decentralization here to stay? By all accounts, signs point to yes. But, as DCT enters the mainstream lexicon, it’s important to distinguish how and where it will benefit clinica

Join for free to read